TENX Tenax Therapeutics Inc.

-0.01  -1%
Previous Close 1.59
Open 1.62
Price To Book 0.83
Market Cap 9724006
Shares 6,154,434
Volume 85,739
Short Ratio
Av. Daily Volume 1,371,058

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 first patient has been randomized - noted March 11, 2019.
Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)
Phase 2b trial did not meet primary endpoint.
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. TENX: HELP Trial Enrollment Underway
  2. Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%
  3. Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial
  4. Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
  5. Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference
  6. Tenax Therapeutics to Present at Biotech Showcase Investor Conference
  7. Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering
  8. Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering
  9. TENX: We Have Liftoff: HELP Site Activated
  10. Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
  11. Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
  12. TENX: Tenax S-1 Filing
  13. How Should You Think About Tenax Therapeutics Inc’s (NASDAQ:TENX) Risks?
  14. Tenax Therapeutics to Present at Upcoming Investor Conferences
  15. TENX: 3Q Start to Pulmonary Hypertension Trial
  16. Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
  17. Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients
  18. Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times?
  19. TENX: Tenax 1Q:18 Results
  20. Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO